Navigation Links
COPD Drug Via Mist Inhaler Could Raise Death Risk: Study
Date:6/14/2011

TUESDAY, June 14 (HealthDay News) -- A mist inhaler with the drug Spiriva is associated with a 52 percent increased risk of death among people with chronic obstructive pulmonary disease (COPD), a new review shows.

The mist inhaler with the soluble form of Spiriva (tiotropium) is approved in 55 countries, but is not yet approved in the United States. However, the powdered form of Spiriva is commonly used to treat COPD patients in the United States.

"Tiotropium is an inhaled drug used commonly in the treatment of COPD. Its major purpose is to reduce obstruction to airflow," explained Dr. Mark Rosen, director of pulmonary rehabilitation at North Shore University Hospital in Manhasset, N.Y., and Long Island Jewish Medical Center in New Hyde Park, N.Y.

"In the U.S., it is available only in the 'Handihaler' device that delivers the drug in a powder form," said Rosen, who was not involved in the new study. "Another form of tiotropium is available in Europe, but not the U.S., in a mist using a 'Respimat' device."

In the new study, researchers led by Dr. Sonal Singh, an assistant professor of general internal medicine at the Johns Hopkins University School of Medicine in Baltimore, analyzed the findings of five published studies that included a total of more than 6,500 patients. They compared the mist inhaler with Spiriva against a mist inhaler with a placebo.

Those who used the inhaler with Spiriva were 52 percent more likely to die than those who used the inhaler with the placebo. There was one excess death due to the mist inhaler with Spiriva for every 124 patients who were treated for a year. Cardiovascular disease is the main reason for the increased risk of death, Singh said.

"What we think is going on is that the mist inhaler is delivering a higher concentration of tiotropium than it should and that may be increasing the risk of death," Singh said in a Hopkins news release.

Rosen said that American patients need not be alarmed, but the findings should give regulators something to consider.

"It is not known why the results of the Handihaler and Respimat are so different, but [it] will give the FDA pause before approving the Respirat in this country," he said.

Another expert said Spiriva can have other serious side effects.

"While it's difficult to compare the different delivery systems' effect on mortality, it is known that certain patients with glaucoma or a history of urinary retention should not use this drug," said Dr. Len Horovitz, a pulmonary specialist at Lenox Hill Hospital in New York City. "It can also cause paradoxical bronchospasm, and severe allergic reactions. Tiotropium causes dry mouth, and can elevate heart rate. Since it is used in COPD, which is associated with cardiac conditions, other cardiac complications are possible."

Patients need to discuss the risks and benefits of COPD treatments with their doctors, Singh advised.

The study appears online June 14 in the BMJ.

COPD, the fourth leading cause of death worldwide, includes emphysema and bronchitis and is typically caused by decades of smoking.

More information

The American Academy of Family Physicians has more about COPD.

-- Robert Preidt

SOURCES: Mark Rosen, M.D., director, pulmonary rehabilitation, North Shore University Hospital, Manhasset, N.Y. and Long Island Jewish Medical Center, New Hyde Park, N.Y.; Len Horovitz, M.D., pulmonary specialist, Lenox Hill Hospital, New York City; Johns Hopkins Medical Institutions, news release, June 14, 2011


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Inhalers Linked to Higher Odds of Diabetes in Asthma, COPD Patients
2. Good Sleep Could Boost Undergrads Learning Capacity
3. Nanotubes could pose health risk to production line staff, study suggests
4. A scientific breakthrough at the IRCM could help understand certain cancers
5. Screening high-risk employees for sleep apnea could save a corporation millions of dollars
6. 1 in 5 heart-attack deaths could be prevented with new drug
7. Simple test could hold key to early diagnosis of cancers
8. MyCare -- the card that could save your life
9. Tai chi could be key to overcoming cognitive effects of chemotherapy
10. Tens of thousands of lives could potentially be saved by key heart failure therapies
11. Groundbreaking male infertility test could bring hope to millions
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
COPD Drug Via Mist Inhaler Could Raise Death Risk: Study
(Date:2/8/2016)... ... February 08, 2016 , ... Discover the Rocky Mountain region’s longest running and ... companies. Attendees also get to see the most incredible gardens and home improvement ... , at the Colorado Convention Center - 700 14th St. Denver CO, is an ...
(Date:2/8/2016)... Nevada (PRWEB) , ... February 08, 2016 , ... ... RowdMap, Inc., will be speaking on how healthcare companies can use newly released ... manage the health of a population and intervene and capture the value they ...
(Date:2/7/2016)... Clarkston, Metamora, Michigan (PRWEB) , ... February 07, ... ... correct pelvic organ prolapse with the latest techniques and the most minimally invasive ... for pelvic organ prolapse, particularly after menopause. Other risk factors include surgery to ...
(Date:2/6/2016)... ... 06, 2016 , ... FOR INFORMATION: Gayle ... SURGICAL CONFERENCE & EXPO , WHAT:     , This conference is the largest ... nurses in attendance to study the latest evidence-based recommendations and resources for ...
(Date:2/6/2016)... ... February 06, 2016 , ... Research has shown that ... reduce the frequency and level of relapse. , At the 2016 ... Purpose,” will explore the critical tasks of the recovery phase and beyond including ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... Feb. 8, 2016 Velano Vascular, a medical ... hospitalized patients and their practitioners, announced today that the ... Velano will use the proceeds from this financing, an ... in January 2015, to support the development and commercialization ... pediatric populations. Philadelphia , ...
(Date:2/8/2016)... 8, 2016  Unilife Corporation ("Unilife" or "Company") (NASDAQ: ... drug delivery systems, today announced that it will release its ... 31, 2015 after market close on February 9, 2016.  At ... to discuss these financial results.    About Unilife ... --> About Unilife Corporation UNIS ...
(Date:2/8/2016)... Feb. 8, 2016 Palatin Technologies, Inc. ... receptor-specific peptide therapeutics for the treatment of diseases ... announced today that the United States Patent and ... Allowance for U.S. Patent Application Serial Number 14/313,258 ... methods of treating female sexual dysfunction using the ...
Breaking Medicine Technology: